NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/11/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization93.99 mln
Float65.96 mln
Earnings Date11/03/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
6.50
Transformational upside
Relative Strength
60
/ 100
Outperforming
Debt / Equity
0.07
Debt-free
ROE
-157
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Biomea Fusion is a US-based medical research company working to bring new treatments to people living with diabetes and obesity. Founded in 2017 and based in San Carlos, California, the company is developing pills that work by blocking a specific protein in the body to influence how cells grow and function. Its primary drug in development, icovamenib, is taken by mouth and targets a protein called menin, which plays a key role in regulating genes and cell activity.
